Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach

Proteins: Structure, Function and Bioinformatics

Volumn 83, Issue 7, 2015, Pages 1209-1224

  Arooj, Mahreen ^a   Sakkiah, Sugunadevi ^b   Cao, Guang Ping ^b   Kim, Songmi ^b   Arulalapperumal, Venkatesh ^b   Lee, Keun Woo ^b  

^a CURTIN UNIVERSITY   (Australia)

^b Gyeongsang National University   (South Korea)

Author keywords

Alzheimer's disease; Biological pathways; Cardiovascular diseases; Chymase; Coagulation cascade; Complement system; Off targets; Systems biology, cancer

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 7; CHYMASE INHIBITOR; ENZYME; GRANZYME; GRANZYME M; KALLIKREIN; LEUKOCYTE ELASTASE; MESOTRYPSIN; SCATTER FACTOR; THROMBIN; TISSUE KALLIKREIN; TISSUE PLASMINOGEN ACTIVATOR; TRYPSIN; UNCLASSIFIED DRUG; CHYMASE; ENZYME INHIBITOR; GZMM PROTEIN, HUMAN; MOLECULAR LIBRARY; PRSS3 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; BINDING SITE; BLEEDING; BLOOD CLOTTING; COMPLEMENT ACTIVATION; DRUG MECHANISM; DRUG REPOSITIONING; DRUG TARGETING; ENZYME DEGRADATION; ENZYME STRUCTURE; FIBRINOLYSIS; HUMAN; INFLAMMATION; LIGAND BINDING; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL ANALYSIS; MOLECULAR DOCKING; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMINOGEN ACTIVATION; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; THROMBOCYTE AGGREGATION; THROMBOSIS; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CHEMISTRY; COMPLEMENT LECTIN PATHWAY; COMPUTER INTERFACE; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MOLECULAR LIBRARY; PATHOLOGY; PHARMACOLOGY; PROCEDURES; STRUCTURE ACTIVITY RELATION; SYSTEMS BIOLOGY;

ALZHEIMER DISEASE; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; CHYMASES; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; DRUG DESIGN; ENZYME INHIBITORS; FIBRINOLYSIS; GRANZYMES; HUMANS; LEUKOCYTE ELASTASE; MOLECULAR DOCKING SIMULATION; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; SYSTEMS BIOLOGY; TISSUE KALLIKREINS; TRYPSIN; USER-COMPUTER INTERFACE;

EID: 84931011063     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.24677     Document Type: Article

References (92)

1. Clements A, Gao B, Yeap S, Wong M, Ali S, Gurney H. Metformin in prostate cancer: two for the price of one. Ann Oncol 2011;22:2556-2560.
2. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005;26:178-182.
3. Yin H, Hamilton AD. Strategies for targeting protein-protein interactions with synthetic agents. Angew Chem Int Ed 2005;44:4130-4163.
4. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4:682-690.
5. Korcsmáros T, Szalay MS, Böde C, Kovács IA, Csermely P. How to design multi-target drugs. 2007:799-808.
6. Amano N, Takai S, Jin D, Ueda K, Miyazaki M. Possible roles of mast cell-derived chymase for skin rejuvenation. Laser Med Sci 2009;24:223-229.
7. Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, Squire IB. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 2007;28:711-718.
8. Takai S, Miyazaki M. Inhibition of transforming growth factor-betaactivation is a novel effect of chymase inactivation. Lett Drug Des Discov 2005;2:19-22.
9. Omoto Y, Tokime K, Yamanaka K, Habe K, Morioka T, Kurokawa I, Tsutsui H, Yamanishi K, Nakanishi K, Mizutani H. Human mast cell chymase cleaves pro-IL-18 and generates a novel and biologically active IL-18 fragment. J Immunol 2006;177:8315-8319.
10. Amir RE, Amir O, Paz H, Sagiv M, Mor R, Lewis BS. Genotype-phenotype associations between chymase and angiotensin-converting enzyme gene polymorphisms in chronic systolic heart failure patients. Genet Med 2008;10:593-598.
11. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003;14:1738-1747.
12. de Garavilla L, Greco MN, Sukumar N, Chen ZW, Pineda AO, Mathews FS, Di Cera E, Giardino EC, Wells GI, Haertlein BJ. A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase molecular mechanisms and anti-inflammatory activity in vivo. J Biol Chem 2005;280:18001-18007.
13. Xie L, Li J, Xie L, Bourne PE. Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput Biol 2009;5:e1000387.
14. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Sandra JH, Niels HJ . Predicting new molecular targets for known drugs. Nature 2009;462:175-181.
15. Kinnings SL, Liu N, Buchmeier N, Tonge PJ, Xie L, Bourne PE . Drug discovery using chemical systems biology: repositioning the safe medicine comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol 2009;5:e1000423.
16. Xie L, Li J, Xie L, Bourne PE. Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput Biol 2009;5:e1000387.
17. Ren J, Xie L, Li WW, Bourne PE. SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison. Nucleic Acids Res 2010;38(suppl 2):W441-W444.
18. Durrant JD, Amaro RE, Xie L, Urbaniak MD, Ferguson MA, Haapalainen A, Chen Z, Di Guilmi AM, Wunder F, Bourne PE. A multidimensional strategy to detect polypharmacological targets in the absence of structural and sequence homology. PLoS Comput Biol 2010;6:e1000648.
19. Röttger R, Kalaghatgi P, Sun P, de Castro Soares S, Azevedo V, Wittkop T, Baumbach J. Density parameter estimation for finding clusters of homologous proteins-tracing actinobacterial pathogenicity lifestyles. Bioinformatics 2013;29:215-222.
20. Aoyama Y, Uenaka M, Kii M, Tanaka M, Konoike T, Hayasaki-Kajiwara Y, Naya N, Nakajima M. Design, synthesis and pharmacological evaluation of 3-benzylazetidine-2-one-based human chymase inhibitors. Bioorg Med Chem 2001;9:3065-3075.
21. Hayashi Y, Iijima K, Katada J, Kiso Y. Structure-activity relationship studies of chloromethyl ketone derivatives for selective human chymase inhibitors. Bioorg Med Chem Lett 2000;10:199-201.
22. 1) region. Bioorg Med Chem Lett 2011;21:4533-4539.
23. Kervinen J, Crysler C, Bayoumy S, Abad MC, Spurlino J, Deckman I, Greco MN, Maryanoff BE, de Garavilla L. Potency variation of small-molecule chymase inhibitors across species. Biochem Pharmacol 2010;80:1033-1041.
24. Venkatachalam C, Jiang X, Oldfield T, Waldman M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Modell 2003;21:289-307.
25. Taha MO, Habash M, Al-Hadidi Z, Al-Bakri A, Younis K, Sisan S. Docking-based comparative intermolecular contacts analysis as new 3-D QSAR concept for validating docking studies and in silico screening: NMT and GP inhibitors as case studies. J Chem Inf Model 2011;51:647-669.
26. Gehlhaar DK, Verkhivker GM, Rejto PA, Sherman CJ, Fogel DR, Fogel LJ, Freer ST. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. Chem Biol 1995;2:317-324.
27. Böhm H-J. Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs. J Comput Aided Mol Des 1998;12:309-309.
28. Stark C, Breitkreutz B-J, Chatr-Aryamontri A, Boucher L, Oughtred R, Livstone MS, Nixon J, Van Auken K, Wang X, Shi X. The BioGRID interaction database: 2011 update. Nucleic Acids Res 2011;39(suppl 1):D698-D704.
29. Prasad TK, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A. Human protein reference database-2009 update. Nucleic Acids Res 2009;37(suppl 1):D767-D772.
30. Miteva YV, Budayeva HG, Cristea IM. Proteomics-based methods for discovery, quantification, and validation of protein-protein interactions. Anal Chem 2012;85:749-768.
31. Chatr-Aryamontri A, Ceol A, Palazzi LM, Nardelli G, Schneider MV, Castagnoli L, Cesareni G. MINT: the Molecular INTeraction database. Nucleic Acids Res 2007;35(suppl 1):D572-D574.
32. Kanehisa M, Susumu G, Yoko S, Masayuki K, Miho F, Mao T . Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 2014;42(Database issue):D199-D205.
33. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-336.
34. Lee M, Kim D. Large-scale reverse docking profiles and their applications. BMC Bioinform 2012;13(Suppl 17):S6.
35. Hajishengallis G. Complement and periodontitis. Biochem Pharmacol 2010;80:1992-2001.
36. Dragon-Durey M-A, Quartier P, Frémeaux-Bacchi V, Blouin J, de Barace C, Prieur A-M, Weiss L, Fridman W-H. Molecular basis of a selective C1s deficiency associated with early onset multiple autoimmune diseases. J Immunol 2001;166:7612-7616.
37. Inoue N, Saito T, Masuda R, Suzuki Y, Ohtomi M, Sakiyama H. Selective complement C1s deficiency caused by homozygous four-base deletion in the C1s gene. Hum Genet 1998;103:415-418.
38. Héja D, Veronika H, Krisztián F, Matthias W, József D, Katalin AK, Péter Z, Péter G, Gábor P . Monospecific inhibitors show that both mannan-binding lectin-associated serine protease-1 (MASP-1) and-2 are essential for lectin pathway activation and reveal structural plasticity of MASP-2. J Biol Chem 2012;287:20290-20300.
39. van't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood 2000;95:1330-1335.
40. Mosesson M. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005;3:1894-1904.
41. Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007;171:715-727.
42. Rand MD, Lock J, Van't Veer C, Gaffney D, Mann K. Blood clotting in minimally altered whole blood. Blood 1996;88:3432-3445.
43. O'Shaughnessy D, Makris M, Lillicrap D. Practical hemostasis and thrombosis. Wiley-Blackwell, 2005.
44. Olivero AG, Charles Ei, Richard G, Kirk R, Dean RA, John F, Thomas R . A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo. J Biol Chem 2005;280:9160-9169.
45. Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol 2011;72:581-592.
46. Schumacher WA, Joseph ML, Mimi LQ, Dietmar AS . Inhibition of factor XIa as a new approach to anticoagulation. Arterioscler Thromb Vasc Biol 2010;30:388-392.
47. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005;129:307-321.
48. Matthews H, Ranson M, Kelso MJ. Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty? Int J Cancer 2011;129:2051-2061.
49. Jankun J, Skrzypczak-Jankun E. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride. Cancer Biochem Biophys 1999;17:109-123.
50. Zhu M, Vijay MG, Lajos S, Ruben MM, Hyounggee B, Sridevi B, Laurence HH, Daniel DVH, Haiyong H . Identification of a novel inhibitor of urokinase-type plasminogen activator. Mol Cancer Therap 2007;6:1348-1356.
51. Mateen FJ, Buchan AM, Hill MD. Outcomes of thrombolysis for acute ischemic stroke in octogenarians versus nonagenarians. Stroke 2010;41:1833-1835.
52. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006;5:785-799.
53. Emami N, Diamandis EP. Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. J Biol Chem 2008;283:3031-3041.
54. Oikonomopoulou K, Hansen KK, Saifeddine M, Vergnolle N, Tea I, Diamandis EP, Hollenberg MD. Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more. Biol Chem 2006;387:677-685.
55. Loessner D, Verena MCQ, Julia K, Eva CW, Dietmar WH, Viktor M, Judith AC . Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance. Gynecol Oncol 2012;127:569-578.
56. Zarghooni M, Soosaipillai A, Grass L, Scorilas A, Mirazimi N, Diamandis EP. Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. Clin Biochem 2002;35:225-231.
57. Sayers TJ, Alan DB, Jerrold MW, Tomoaki H, William EB, Gordon WW, Janice MK, Mark JS . The restricted expression of granzyme M in human lymphocytes. J Immunol 2001;166:765-771.
58. Cullen SP, Afonina IS, Donadini R, Lüthi AU, Medema JP, Bird PI, Martin SJ. Nucleophosmin is cleaved and inactivated by the cytotoxic granule protease granzyme M during natural killer cell-mediated killing. J Biol Chem 2009;284:5137-5147.
59. Belaaouaj A, Kim KS, Shapiro SD. Degradation of outer membrane protein A in Escherichia coli killing by neutrophil elastase. Science 2000;289:1185-1187.
60. Dale DC, Link DC. The many causes of severe congenital neutropenia. N Engl J Med 2009;360:3.
61. Henriksen PA, Mary H, Zhou X, Jun W, Chris H, Rudolph AR, David JW, Yuri VK, Jean M . Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-κB-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immunol 172.7 2004:4535-4544.
62. Szmola R, Kukor Z, Sahin-Tóth M. Human mesotrypsin is a unique digestive protease specialized for the degradation of trypsin inhibitors. J Biol Chem 2003;278:48580-48589.
63. Hockla A, Radisky DC, Radisky ES. Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Res Treat 2010;124:27-38.
64. Weickhardt AJ, Benjamin S, Joseph MBe, Gregory G, Xian L, Paul ABJ, Dara LA . Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene addicted non-small cell lung cancer. J Thorac Oncol 2012;7:1807.
65. Moh'd AS, Robinson JL, Navaneetham D, Sinha D, Madden BJ, Walsh PN, Radisky ES. The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin. J Biol Chem 2010;285:1939-1949.
66. Tchougounova E, Peller G. Regulation of extravascular coagulation and fibrinolysis by heparin-dependent mast cell chymase. FASEB J 2001;15:2763-2765.
67. Pejler G, Karlström A. Thrombin is inactivated by mast cell secretory granule chymase. J Biol Chem 1993;268:11817-11822.
68. Hamuro T, Hiroshi K, Yujiro A, Kinta H, Yuushi O, Youichi K, Takashi K, Sadaaki I, Shintaro K . Tissue factor pathway inhibitor is highly susceptible to chymase-mediated proteolysis. FEBS J 2007;274:3065-3077.
69. Kakimoto K, Shinji T, Mitsuyuki M, Kumi I, Yukiko Y, Takuya I, Denan J, Eiji U, Kazuhide Hi . Significance of chymase-dependent matrix metalloproteinase-9 activation on indomethacin-induced small intestinal damages in rats. J Pharmacol Exp Ther 2010;332:684-689.
70. Chmelar J, Carlo JOa, Pavlina R, Ivo MBF, Zuzana K, Gunnar P, Peter K . A tick salivary protein targets cathepsin G and chymase and inhibits host inflammation and platelet aggregation. Blood 2011;117:736-744.
71. Kyriakides C, William GAJ, Yong W, Joanne F, Lester K, Francis DMJ, Herbert BH . Mast cells mediate complement activation after acid aspiration. Shock 2001;16:21-24.
72. Guillabert A, Valérie W, Benjamin B, Véronique G, Virginie I, Marc P, David C . Role of neutrophil proteinase 3 and mast cell chymase in chemerin proteolytic regulation. J Leukoc Biol 2008;84:1530-1538.
73. Whitebread S, Hamon J, Bojanic D, Urban L. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today 2005;10:1421-1433.
74. Campillos M, Kuhn M, Gavin A-C, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 2008;321:263-266.
75. Xie L, Xie L, Bourne PE. A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery. Bioinformatics 2009;25:i305-i312.
76. Zhang P, Zhang J, Sheng H, Russo JJ, Osborne B, Buetow K. Gene functional similarity search tool (GFSST). BMC Bioinform 2006;7:135.
77. Couto FM, Silva MJ, Coutinho PM. Measuring semantic similarity between gene ontology terms. Data knowl Eng 2007;61:137-152.
78. Moustakas DT, Lang PT, Pegg S, Pettersen E, Kuntz ID, Brooijmans N, Rizzo RC. Development and validation of a modular, extensible docking program: DOCK 5. J Comput Aided Mol Des 2006;20:601-619.
79. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455-461.
80. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved protein-ligand docking using GOLD. Proteins 2003;52:609-623.
81. Dessalew N, Bharatam PV. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity. Eur J Med Chem 2007;42:1014-1027.
82. Liu S, Lu H, Zhao Q, He Y, Niu J, Debnath AK, Wu S, Jiang S. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim Biophys Acta 2005;1723:270-281.
83. Kroemer RT. Structure-based drug design: docking and scoring. Curr Protein Pept Sci 2007;8:312-328.
84. Salvador JA, Moreira VM, Silvestre SM. Steroidal CYP17 inhibitors for prostate cancer treatment: from concept to clinic. 2013.
85. Montes M, Miteva MA, Villoutreix BO. Structure-based virtual ligand screening with LigandFit: pose prediction and enrichment of compound collections. Proteins 2007;68:712-725.
86. Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov 2009;9:43-56.
87. Beck KD, Nguyen HX, Galvan MD, Salazar DL, Woodruff TM, Anderson AJ. Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment. Brain 2010;133:433-447.
88. Mercer PF, Chambers RC. Coagulation and coagulation signalling in fibrosis. Biochim Biophys Acta 2013;1832:1018-1027.
89. Yildirim MA, Goh K-I, Cusick ME, Barabási A-L, Vidal M. Drug-target network. Nat Biotechnol 2007;25:1119.
90. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006;5:649-659.
91. Roy A, Zhang Y. Recognizing protein-ligand binding sites by global structural alignment and local geometry refinement. Structure 2012;20:987-997.
92. Badis G, Berger MF, Philippakis AA, Talukder S, Gehrke AR, Jaeger SA, Chan ET, Metzler G, Vedenko A, Chen X. Diversity and complexity in DNA recognition by transcription factors. Science 2009;324:1720-1723.